Cubist Systematic Strategies LLC Makes New Investment in InflaRx (NASDAQ:IFRX)

Cubist Systematic Strategies LLC acquired a new position in shares of InflaRx (NASDAQ:IFRX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 22,437 shares of the company’s stock, valued at approximately $55,000.

Other large investors also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of InflaRx during the 4th quarter worth $1,576,000. Northern Trust Corp grew its stake in shares of InflaRx by 1,933.1% during the 4th quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock worth $1,647,000 after purchasing an additional 634,045 shares during the period. Walleye Capital LLC acquired a new position in shares of InflaRx during the 4th quarter worth $51,000. Commonwealth Equity Services LLC grew its stake in shares of InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after purchasing an additional 19,000 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock worth $119,000 after purchasing an additional 11,900 shares during the period. Hedge funds and other institutional investors own 42.39% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on IFRX shares. Guggenheim upped their price target on shares of InflaRx from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, March 26th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of InflaRx in a research note on Friday, March 21st. Cantor Fitzgerald assumed coverage on shares of InflaRx in a research note on Tuesday, April 29th. They issued an “overweight” rating and a $10.00 price objective on the stock. Finally, Oppenheimer assumed coverage on shares of InflaRx in a research note on Thursday, May 8th. They issued an “outperform” rating and a $6.00 price objective on the stock.

InflaRx Trading Up 6.6%

Shares of NASDAQ IFRX opened at $1.77 on Tuesday. InflaRx has a 52 week low of $0.82 and a 52 week high of $2.82. The stock has a market cap of $118.83 million, a price-to-earnings ratio of -1.64 and a beta of 1.57. The company’s 50-day moving average price is $1.29 and its 200 day moving average price is $1.83.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million. As a group, research analysts expect that InflaRx will post -1.04 earnings per share for the current year.

InflaRx Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.